Table 1.

Demographic, clinical and cachexia domain characteristics of the study population (n = 120 cancer patients with metastatic disease, stage UICC IV).

Cohort	Cachexia	No Cachexia	P-value
Sample size (n)	78	42
Patient data
Age,1 year	68 (10)	65 (12)	0.074
Male3	46 (59)	17 (40)	0.053
ECOG-PS,3 score ≤1	44 (56)	37 (88)	<0.001
Body mass index (BMI)
Height,1 cm	172 (10)	172 (10)	0.880
Weight,1 kg	62 (12)	78 (13)	<0.001
BMI,1 kg/m2	20.9 (3.0)	26.4 (3.6)	<0.001
Weight loss (WL)
WL,1 kg	-6.5 (1.8)	-0.2 (1.6)	<0.001
WL,1%	-9.7 (3.6)	-0.3 (2.0)	<0.001
Food intake
Reduced,1 (vs. unchanged)	59 (76)	11 (26)	<0.001
Appetite loss
ESAS Score,2 score 0-10	4.0 (3.0, 5.0)	2.0 (0.25, 2.0)	<0.001
C-reactive protein (CRP)
CRP values2 (mg/dl)	37 (9, 61)	14 (7, 30)	<0.001
Clinical data
Smoking3	23 (29)	10 (24)	0.682
Alcohol3	26 (33)	17 (40)	0.713
Vegetarian3	5 (6.4)	2 (4.7)	1.0
Diabetes	17 (21)	7 (17)	0.644
Cancer type
Colon Cancer3	25 (32)	16 (38.1)	0.707
Pancreatic Cancer3	23 (29)	9 (21)	0.532
Gastric Cancer3	20 (26)	10 (24)	1.0
Liver Cancer3	7 (9)	5 (12)	0.754
Ovarian Cancer3	3 (3.8)	2 (4.8)	1.0
Cancer stage
Metastatic Disease (stage UICC IV)3	78 (100)	42 (100)	1.0
Medication
Morphine3	20 (25)	7 (17)	0.499
Novaminsulfon3	23 (29)	9 (21)	0.523
Non-steroidal Analgetics3	14 (18)	10 (24)	0.642
Pantozol3	8 (10)	7 (16)	0.403
Diuretics3	7 (9)	5 (12)	0.754
Antibiotics (within ≤2 weeks)3	20 (25)	10 (24)	1.0
No Antibiotics (within ≥3 months)3	58 (75)	32 (76)	1.0

¹Mean (standard deviation) [normal data distribution]; Welch two sample t-test applied to compare groups.

²Median (quartile 1, quartile 3) [outside normal distribution]; Wilcoxon rank sum test applied to compare groups.

³Count (percentage); Pearson´s Chi-squared test applied to compare groups.